✦ LIBER ✦

1083 Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma (NSCLC) treated by chemotherapy and radiotherapy

✍ Scribed by Berghmans, T.; Lafitte, J.J.; Thiriaux, J.; VanHoutte, P.; Lecomte, J.; Efremidis, A.; Giner, V.; Paesmans, M.; Klastersky, J.; Sculier, J.P.

Book ID: 122560166
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 168 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(03)91109-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival is better predicted with a new

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy

✍ Berghmans, T.; Lafitte, J.J.; Thiriaux, J.; VanHoutte, P.; Lecomte, J.; Efremidi 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 126 KB

Survival analysis of a serie of 100 pati

Survival analysis of a serie of 100 patients with locally advanced unresectable non-small cell lung cancer (NSCLC) treated with a sequential schedule of cisplatin-based chemotherapy (CBC) and radiotherapy (RDT)

✍ Vadell-Nadal, C; Algara, M; Gallén, M; Curull, V; Pérez, C; Auñón, C; Fabregat, 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Effect of concurrent chemotherapy on loc

Effect of concurrent chemotherapy on local control in stage III non small cell lung carcinoma (NSCLC) treated with standard fractionation radiotherapy (RT) : Results of a prospective analysis in 123 patients (PTS)

✍ F. Reboul; Y. Brower; P. Vincent; B. Chauvet; C.Félix Faure; M. Taulelle 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 147 KB

PD-039 Induction chemotherapy with cispl

PD-039 Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation (CCR) with biweekly gemcitabine in unresectable stage III non small cell lung cancer (NSCLC): Final results of a phase II study

✍ Blanco, R.; Solé, J.; Nogué, M.; Montesinos, J.; Gallardo, E.; Vadell, C.; Mesía 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 124 KB

A phase II trial of individualized respo

A phase II trial of individualized response-based induction chemotherapy (IC) of mitomycin-C, vindesine, cisplatin (MVP) followed by thoracic radiotherapy (TRT) with daily low-dose carboplatin (CBDCA) for the treatment of unresectable stage III non-small-cell lung cancer (NSCLC)

✍ Shinbo, T; Makino, M; Tsukada, H; Yokoyama, A; Saitou, M; Kurita, Y 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 230 KB

2136 Does concurrent chemotherapy improv

2136 Does concurrent chemotherapy improve local control and survival over radiotherapy alone or induction chemotherapy in stage III non-small cell lung cancer (NSCLC)? Results at 3 years in 140 patients (PTS) with a minimum follow-up of 24 months

✍ F. Reboul; Y. Brewer; P. Vincent; B. Chauvet; C.Félix Faure; M. Taulelle 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 133 KB